Mucosal administration of low-dose cell-associated feline immunodeficiency virus promotes viral latency

Journal of Infectious Diseases

Volumn 195, Issue 8, 2007, Pages 1184-1188

  Assogba, Barnabe Dossou ^a   Leavell, Sarah ^a   Porter, Kyle ^a   Burkhard, Mary Jo ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHORBOL 13 ACETATE 12 MYRISTATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAT; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; EX VIVO STUDY; FELINE IMMUNODEFICIENCY VIRUS; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; LATENT VIRUS INFECTION; MUCOSA; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS LATENCY; VIRUS REACTIVATION; VIRUS TRANSMISSION;

ANIMALS; CAT DISEASES; CATS; DISEASE MODELS, ANIMAL; DISEASE RESERVOIRS; FEMALE; IMMUNODEFICIENCY VIRUS, FELINE; LENTIVIRUS INFECTIONS; MUCOUS MEMBRANE; PROVIRUSES; VAGINA; VIREMIA; VIRUS LATENCY;

EID: 34047207439     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/512861     Document Type: Article

References (15)

1. Koning FA, van der Vorst TJ, Schuitemaker H. Low levels of human immunodeficiency virus type 1 DNA in high-risk seronegative men. J Virol 2005; 79:6551-3.
2. Imagawa DT, Lee MH, Wolinsky SM, et al. Human immunodeficiency virus type 1 infection in homosexual men who remain seronegative for prolonged periods. N Engl J Med 1989; 320:1458-62.
3. +-T-cell proliferative responses in rhesus macaques that were transiently viremic after intravaginal inoculation of SIV. J Virol 1998; 72:10029-35.
4. Burkhard MJ, Dean GA. Transmission and immunopathogenesis of FIV in cats as a model for HIV. Current HIV Research 2003; 1:15-29.
5. Stevens R, Howard KE, Nordone S, Burkhard M, Dean GA. Oral immunization with recombinant Listeria monocytogenes controls virus load after vaginal challenge with feline immunodeficiency virus. J Virol 2004; 78:8210-8.
6. Burkhard MJ, Obert LA, O'Neil LL, Diehl LJ, Hoover EA. Mucosal transmission of cell-associated and cell-free feline immunodeficiency virus. AIDS Res Hum Retroviruses 1997; 13:347-55.
7. Shacklett BL. Understanding the "lucky few": the conundrum of HIV-exposed, seronegative individuals. Curr HIV/AIDS Rep 2006; 3:26-31.
8. Miller CJ, Marthas M, Torten J, et al. Intravaginal inoculation of rhesus macaques with cell-free simian immunodeficiency virus results in persistent or transient viremia. J Virol 1994; 68:6391-400.
9. Zhu T, Hu SL, Feng F, et al. Persistence of low levels of simian immunodeficiency virus in macaques that were transiently viremic by conventional testing. Virology 2004; 323:208-19.
10. Zhu T, Corey L, Hwangbo Y, et al. Persistence of extraordinarily low levels of genetically homogeneous human immunodeficiency virus type 1 in exposed seronegative individuals. J Virol 2003; 77:6108-16.
11. McDermott AB, Mitchen J, Piaskowski S, et al. Repeated low-dose mucosal simian immunodeficiency virus SIVmac239 challenge results in the same viral and immunological kinetics as high-dose challenge: a model for the evaluation of vaccine efficacy in nonhuman primates. J Virol 2004; 78:3140-4.
12. + antiviral response that correlates with reduction of cell-associated virus. J Infect Dis 1998; 177:18-25.
13. + cell anti-HIV factor (CAF). Trends Immunol 2003; 24:628-32.
14. - cells. Virology 2005; 335:212-21.
15. Veazey RS, Lackner AA. Getting to the guts of HIV pathogenesis. J Exp Med 2004; 200:697-700.